Ustekinumab—Phase II StudySecukinumab phase II trial is a monoclonal antibody against IL-17A for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.MOR106 p/monoclonal antibodies against IL-17C. The gene discussed is IL17A; the disease is psoriatic arthritis.